Medical Laboratory
Accredited to ISO15189:2012

UKAS MEDICAL 9376

oncologica®

Leading a new era of precision oncology

Oncofocus®

Precision Oncology

ONCOFOCUS® TEST REPORT

Oncologica UK Ltd
Suite 2, The Newnham Building
Chesterford Research Park, Little Chesterford
Cambridge, CB10 1XL
Tel: +44(0)1223 785327
Email: info@oncologica.com

ONC18	-		
Surname	-	**Requester**	-
Forename	-	**Contact details**	-
DOB	-	**Date requested**	-
Gender	-		
Histology #	-	**Tumour %**	80%
Primary site	Sacrum Coccyx	**Tumour %**	-
Tumour subtype	Ewings Sarcoma	**(macrodissected)**	
Tissue Type	Sacrococcygeal		

Comment:
The DNA and RNA extracted from this sample were of optimal quality. The Oncofocus assay on which the sample was run met all assay specific quality metrics.

Oncofocus currently targets 505 genes covering oncogenes, fusion genes, genes susceptible to copy number variation and tumour suppressors. Actionable genetic variants detected by Oncofocus are currently linked to 687 anti-cancer targeted therapies/therapy combinations.

The following actionable variants were detected:

Within the 'Current Clinical Trials Information' section of this report, starting on page 4, the NCT numbers are hyperlinks to the clinicaltrials.gov webpages which should be accessed to gain further trial specific information

Sample Cancer Type: Soft Tissue Sarcoma

Clinically Significant Biomarkers

Indicated Contraindicated

Genomic Alteration	Alt Allele Freq	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
SLX4 mutation p.(Q1604) c.4810C>T*	10.34%	Clinical trials and/or off-label	Clinical trials and/or off-label	8
PALB2 deletion (copy no = 0.99)		Clinical trials and/or off-label	Clinical trials and/or off-label	6
STK11 deletion (copy no = 0.80)		Clinical trials and/or off-label	Clinical trials and/or off-label	6
SMARCB1 deletion (copy no = 0.91)		Clinical trials and/or off-label	Clinical trials and/or off-label	1

Sources included in relevant therapies: EMA[1], FDA[2], ESMO, NCCN

Hotspot variants with >10% alternate allele reads are classified as 'detected' with an assay sensitivity and positive predictive value(PPV) of 99%. Copy number variants; amplifications of CN> 6 with the 5% confidence value of ≥4 after normalization and deletions with 95% CI ≤1 are classified as present when the tumour% >50% with a sensitivity of 80% and PPV 100%. Gene Fusions are reported when occurring in >40 counts and meeting the thresholds of assay specific internal RNA quality control with a sensitivity of 92% and PPV of 99%. Supplementary technical information is available upon request. *Please note this version of the Oncofocus test is an upgraded version to that accredited on our schedule*

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

Oncologica UK Ltd
Suite 2, The Newnham Building
Chesterford Research Park, Little Chesterford
Cambridge, CB10 1XL
Tel: +44(0)1223 785327
Email: info@oncologica.com

Tier Criteria Met

Genomic Alteration	Tier Classification for Soft Tissue Sarcoma
SLX4 mutation Tier: IIC	IIC: Biomarker is an inclusion criteria for clinical trials
PALB2 deletion Tier: IIC	IIC: Biomarker is an inclusion criteria for clinical trials
STK11 deletion Tier: IIC	IIC: Biomarker is an inclusion criteria for clinical trials
SMARCB1 deletion Tier: IIC	IIC: Biomarker is an inclusion criteria for clinical trials

Reference: Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.

Relevant Therapy Summary

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⚠ Both for use and contraindicated ✖ No evidence

SLX4 mutation

Relevant Therapy	EMA	FDA	ESMO	NCCN	Clinical Trials*
durvalumab + olaparib	✖	✖	✖	✖	● (II)
niraparib	✖	✖	✖	✖	● (II)
prexasertib	✖	✖	✖	✖	● (II)
talazoparib	✖	✖	✖	✖	● (II)
BAY-1895344	✖	✖	✖	✖	● (I/II)
PNT-737 + chemotherapy	✖	✖	✖	✖	● (I/II)
VX-970, VX-970 + chemotherapy	✖	✖	✖	✖	● (I/II)

PALB2 deletion

Relevant Therapy	EMA	FDA	ESMO	NCCN	Clinical Trials*
durvalumab + olaparib	✖	✖	✖	✖	● (II)
prexasertib	✖	✖	✖	✖	● (II)
talazoparib	✖	✖	✖	✖	● (II)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

Oncologica UK Ltd
Suite 2, The Newnham Building
Chesterford Research Park, Little Chesterford
Cambridge, CB10 1XL
Tel: +44(0)1223 785327
Email: info@oncologica.com

Relevant Therapy Summary (continued)

● In this cancer type ○ In other cancer type ◑ In this cancer type and other cancer types ⊘ Contraindicated ⚠ Both for use and contraindicated ✖ No evidence

PALB2 deletion (continued)

Relevant Therapy	EMA	FDA	ESMO	NCCN	Clinical Trials*
BAY-1895344	✖	✖	✖	✖	● (I/II)
PNT-737 + chemotherapy	✖	✖	✖	✖	● (I/II)
BGB-A317 + pamiparib	✖	✖	✖	✖	● (I)

STK11 deletion

Relevant Therapy	EMA	FDA	ESMO	NCCN	Clinical Trials*
capivasertib + olaparib	✖	✖	✖	✖	● (II)
sapanisertib	✖	✖	✖	✖	● (II)
temsirolimus	✖	✖	✖	✖	● (II)
capivasertib	✖	✖	✖	✖	● (I)
gedatolisib + palbociclib	✖	✖	✖	✖	● (I)
palbociclib + pictilisib, palbociclib + taselisib	✖	✖	✖	✖	● (I)

SMARCB1 deletion

Relevant Therapy	EMA	FDA	ESMO	NCCN	Clinical Trials*
pembrolizumab	✖	✖	✖	✖	● (II)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

Relevant Therapy Details

Current Clinical Trials Information

Clinical Trials information is current as of 2018-09-04. For the most up-to-date information regarding a particular trial, search www.clinicaltrials.gov by NCT ID or search local clinical trials authority website by local identifier listed in 'Other identifiers'.

SLX4 mutation

NCT02797977
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer

Cancer type: Soft Tissue Sarcoma

Variant class: DNA repair pathway

Other identifiers: 198606, 30498, CRUKD/16/005, EudraCT Number: 2015-004467-36, PNT737-02, SRA737-02

Population segments: BRCA, Fourth line or greater, KRAS, Second line, Stage III, Stage IV, Third line

Phase: I/II

Therapy: PNT-737 + chemotherapy

Locations: Spain, United Kingdom

NCT03207347
A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response (DDR) Pathway Deficient Neoplasms (UF-STO-ETI-001)

Cancer type: Unspecified Cancer

Variant class: SLX4 mutation

Other identifier: UF-STO-ETI-001

Population segments: (N/A), Second line

Phase: II

Therapy: niraparib

Location: United States

US State: FL

US Contact: Ashton Monismith [352-265-0680 ext 87657; amonismith@ufl.edu]

No NCT ID - see other identifier(s)
Single Arm, Open label, Signal Seeking, Phase IIa Trial Of The Activity Of Olaparib In Combination With Durvalumab In Patients With Tumours With Homologous Recombination Repair Defects

Cancer type: Unspecified Solid Tumor

Variant class: FANC mutation

Other identifiers: ACTRN12617001000392, MoST Addendum 3, U1111-1182-6652

Population segments: Second line, Stage III, Stage IV

Phase: II

Therapy: durvalumab + olaparib

Location: Australia

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

Oncologica UK Ltd
Suite 2, The Newnham Building
Chesterford Research Park, Little Chesterford
Cambridge, CB10 1XL
Tel: +44(0)1223 785327
Email: info@oncologica.com

SLX4 mutation (continued)

NCT02401347
A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild-Type Patients With (i) Advanced Triple-Negative Breast Cancer and Homologous Recombination Deficiency, and (ii) Advanced HER2-Negative Breast Cancer or Other Solid Tumors With Either a Mutation in Homologous Recombination Pathway Genes Talazoparib Beyond BRCA (TBB) Trial

Cancer type: Unspecified Solid Tumor

Variant class: FANC mutation

Other identifiers: BRS0050, NCI-2015-00036, TBB

Population segments: HER2 negative, Second line or greater/Refractory/Relapsed, Stage III, Stage IV, Triple receptor negative

Other inclusion criteria: ERBB2 negative

Phase: II

Therapy: talazoparib

Location: United States

US State: CA

US Contact: Pei Jen Chang [650-725-0866; peijenc@stanford.edu]

NCT02873975
A Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair Deficiency

Cancer type: Unspecified Solid Tumor

Variant class: Fanconi anemia pathway

Other identifiers: 16-281, I4D-MC-E006, NCI-2016-01564

Population segments: Second line, Stage III, Stage IV

Phase: II

Therapy: prexasertib

Location: United States

US State: MA

US Contact: Dr. Geoffrey Shapiro [617-632-4942; Geoffrey_Shapiro@dfci.harvard.edu]

NCT02286687
Phase II Study of the PARP Inhibitor BMN 673 (Talazoparib Tosylate) in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in PTEN or PTEN Loss, a Homologous Recombination Defect, Mutations/ Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer)

Cancer type: Unspecified Cancer

Variant class: Fanconi anemia pathway

Other identifiers: 2013-0961, NCI-2014-02494

Population segments: Fourth line or greater, Stage III, Stage IV

Phase: II

Therapy: talazoparib

Location: United States

US State: TX

US Contact: Dr. Sarina Piha-Paul [713-563-1930]

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

SLX4 mutation (continued)

No NCT ID - see other identifier(s)
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/ Pharmacodynamic Profile of VX-970 as a Single Agent in Combination with Carboplatin in Subjects with Advanced Solid Tumors

Cancer type: Unspecified Solid Tumor

Variant class: DNA repair mutation

Other identifiers: EudraCT Number: 2013-005100-34, VX13-970-002

Population segments: (N/A), Adenocarcinoma, HER2 negative, Second line or greater/ Refractory/Relapsed, Stage III, Stage IV, Triple receptor negative

Phase: I/II

Therapies: VX-970, VX-970 + chemotherapy

Location: United Kingdom

NCT03188965
An Open-label, First-in-human, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

Cancer type: Unspecified Solid Tumor

Variant class: DNA repair pathway

Other identifiers: 18594, 2017-0186, BAY1895344/18594, EudraCT Number: 2016-004484-39, IRAS ID-218516, NCI-2018-00206, Trial ID: 16754

Population segments: Adenocarcinoma, Aggressive, Diffuse large B-cell lymphoma (DLBCL), Hormone refractory, Indolent, Mantle cell lymphoma (MCL), Second line, Squamous Cell, Stage III, Stage IV

Phase: I/II

Therapy: BAY-1895344

Locations: Canada, Singapore, Switzerland, United Kingdom, United States

US State: TX

US Contact: Bayer Clinical Trials Contact [888-842-2937; clinical-trials-contact@bayer.com]

PALB2 deletion

NCT02797977
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer

Cancer type: Soft Tissue Sarcoma

Variant class: DNA repair pathway

Other identifiers: 198606, 30498, CRUKD/16/005, EudraCT Number: 2015-004467-36, PNT737-02, SRA737-02

Population segments: BRCA, Fourth line or greater, KRAS, Second line, Stage III, Stage IV, Third line

Phase: I/II

Therapy: PNT-737 + chemotherapy

Locations: Spain, United Kingdom

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

PALB2 deletion (continued)

No NCT ID - see other identifier(s)
Single Arm, Open label, Signal Seeking, Phase IIa Trial Of The Activity Of Olaparib In Combination With Durvalumab In Patients With Tumours With Homologous Recombination Repair Defects

Cancer type: Unspecified Solid Tumor

Variant class: PALB2 deletion

Other identifiers: ACTRN12617001000392, MoST Addendum 3, U1111-1182-6652

Population segments: Second line, Stage III, Stage IV

Phase: II

Therapy: durvalumab + olaparib

Location: Australia

NCT02286687
Phase II Study of the PARP Inhibitor BMN 673 (Talazoparib Tosylate) in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in PTEN or PTEN Loss, a Homologous Recombination Defect, Mutations/ Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer)

Cancer type: Unspecified Cancer

Variant class: PALB2 deletion

Other identifiers: 2013-0961, NCI-2014-02494

Population segments: Fourth line or greater, Stage III, Stage IV

Phase: II

Therapy: talazoparib

Location: United States

US State: TX

US Contact: Dr. Sarina Piha-Paul [713-563-1930]

NCT02873975
A Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair Deficiency

Cancer type: Unspecified Solid Tumor

Variant class: Fanconi anemia pathway

Other identifiers: 16-281, I4D-MC-E006, NCI-2016-01564

Population segments: Second line, Stage III, Stage IV

Phase: II

Therapy: prexasertib

Location: United States

US State: MA

US Contact: Dr. Geoffrey Shapiro [617-632-4942; Geoffrey_Shapiro@dfci.harvard.edu]

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

PALB2 deletion (continued)

NCT03188965
An Open-label, First-in-human, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

Cancer type: Unspecified Solid Tumor

Variant class: DNA repair pathway

Other identifiers: 18594, 2017-0186, BAY1895344/18594, EudraCT Number: 2016-004484-39, IRAS ID-218516, NCI-2018-00206, Trial ID: 16754

Population segments: Adenocarcinoma, Aggressive, Diffuse large B-cell lymphoma (DLBCL), Hormone refractory, Indolent, Mantle cell lymphoma (MCL), Second line, Squamous Cell, Stage III, Stage IV

Phase: I/II

Therapy: BAY-1895344

Locations: Canada, Singapore, Switzerland, United Kingdom, United States

US State: TX

US Contact: Bayer Clinical Trials Contact [888-842-2937; clinical-trials-contact@bayer.com]

NCT02660034
A Phase I/Ib, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors

Cancer type: Unspecified Solid Tumor

Variant class: HRR pathway

Other identifiers: 16-183, A317/290, BGB-A317/BGB-290_Study_001, CT783, NCI-2018-00791

Population segments: HER2 negative, Second line, Stage III, Stage IV, Triple receptor negative

Phase: I

Therapy: BGB-A317 + pamiparib

Locations: Australia, New Zealand, Spain, United States

US States: AZ, CA, CO, FL, MA, NY, PA, TN, TX, VA

US Contact: Dr. Ginny Paton [clinicaltrials@beigene.com]

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

STK11 deletion

NCT02987959
Phase II Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas With Dysregulation of the mTOR Pathway

Cancer type: Soft Tissue Sarcoma

Variant class: PI3K/AKT/MTOR pathway

Other identifiers: 16-1047, SAR-081

Population segments: Locally advanced, Metastatic, Second line, Stage IV, Unresectable

Phase: II

Therapy: sapanisertib

Location: United States

US State: PA

US Contact: Dr. Sujana Movva [888-369-2427; sujana.movva@fccc.edu]

NCT03297606
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial

Cancer type: Unspecified Solid Tumor

Variant class: STK11 aberration

Other identifiers: CA209-9DL, CAPTUR, ESR-17-12831, ML39800, PM1, WI233446

Population segments: Aggressive, Diffuse large B-cell lymphoma (DLBCL), Extranodal marginal zone B-cell lymphoma (MALT), First line, Follicular lymphoma (FL), Indolent, Lymphoblastic lymphoma (LBL), Mantle cell lymphoma (MCL), Other subtype, Second line, Stage III, Stage IV, Waldenstrom`s macroglobulinemia (WM)

Phase: II

Therapy: temsirolimus

Location: Canada

NCT02576444
A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors

Cancer type: Unspecified Solid Tumor

Variant class: PI3K/AKT/MTOR pathway

Other identifiers: 1508016363, 16-314, NCI-2016-00922, OLAPCO, VICCMD1672

Population segments: First line, Second line, Stage IV

Phase: II

Therapy: capivasertib + olaparib

Location: United States

US States: CT, MA, OH, TN

US Contact: Manuel Avedissian [203-737-3669; manuel.avedissian@yale.edu]

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

STK11 deletion (continued)

NCT01226316
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies

Cancer type: Unspecified Solid Tumor

Variant class: PI3K/AKT/MTOR pathway

Other identifiers: 0C-14-10, 102084, 14-214, 14-430, 2014-0160, CR1322AZ, CSET 2365, D3610C00001, EudraCT Number: 2010-022167-35, IRAS ID: 62131, JapicCTI-152844, M10AZD, NCI-2014-01803, NL33755.031.10, P1TGIVEN, PRO 09

Population segments: (N/A), Adenocarcinoma, Estrogen receptor positive, Fourth line or greater, HER2 positive, Hormone refractory, Second line, Stage III, Stage IV, Third line

Exclusion criteria variant classes: BRAF mutation, HRAS mutation, KRAS mutation, NRAS mutation

Phase: I

Therapy: capivasertib

Locations: Canada, Denmark, France, Italy, Japan, Singapore, Spain, United States

US States: CA, CO, NY, OK, PA, TN, TX

US Contact: AstraZeneca Clinical Study Information Center [877-240-9479; information.center@astrazeneca.com]

NCT03065062
Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Cancer type: Unspecified Solid Tumor

Variant class: PI3K/AKT/MTOR pathway

Other identifiers: 16-499, NCI-2017-00434

Population segments: Second line, Squamous Cell, Stage III, Stage IV

Phase: I

Therapy: gedatolisib + palbociclib

Location: United States

US State: MA

US Contact: Dr. Nicole Chau [617-632-3090]

NCT02389842
PIPA: A Phase Ib Study to Assess the Safety, Tolerability and Efficacy of the PI3K Inhibitors, Taselisib (GDC-0032) or Pictilisib (GDC-0941), in Combination With PAlbociclib, With the Subsequent Addition of Fulvestrant in PIK3CA-mutant Breast Cancers

Cancer type: Unspecified Solid Tumor

Variant class: PI3K/AKT/MTOR pathway

Other identifiers: CCR4191, EudraCT Number: 2014-002658-37, IRAS ID:159997, PIPA

Population segments: Estrogen receptor positive, Fourth line or greater, HER2 negative, HER2 positive, KRAS, Stage III, Stage IV, Triple receptor negative

Phase: I

Therapies: palbociclib + pictilisib, palbociclib + taselisib

Location: United Kingdom

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

SMARCB1 deletion

NCT03012620
Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types

Cancer type: Soft Tissue Sarcoma

Variant class: SMARCB1 deletion

Other identifiers: EudraCT Number: 2016-002260-14, UC0105/1612

Population segments: Aggressive, Anaplastic, Follicular, Fourth line or greater, Locally advanced, Medullary, Metastatic, Papillary, Recurrent, Stage III, Stage IV, Third line, Unresectable

Phase: II

Therapy: pembrolizumab

Location: France

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

Evidence Summary by Variant Class

A variant class hierarchy was created to summarize gene variants with associated clinical evidence. Evidence items refers to citations across the different global data sources.

SLX4 mutation

Variant Class	Evidence Items
DNA repair pathway	4
↳ DNA repair mutation	1
↳ SLX4 mutation	1
Fanconi anemia pathway	3
↳ FANC aberration	0
↳ FANC mutation	2
↳ SLX4 mutation	1

PALB2 deletion

Variant Class	Evidence Items
DNA repair pathway	4
↳ PALB2 deletion	2
HRR pathway	1
↳ PALB2 deletion	2
Fanconi anemia pathway	3
↳ FANC aberration	0
↳ FANC deletion	0
↳ PALB2 deletion	2

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

Evidence Summary by Variant Class (continued)

A variant class hierarchy was created to summarize gene variants with associated clinical evidence. Evidence items refers to citations across the different global data sources.

STK11 deletion

Variant Class	Evidence Items
PI3K/AKT/MTOR pathway	5
↳ STK11 aberration	1
↳ STK11 deletion	0

SMARCB1 deletion

Variant Class	Evidence Items
SMARCB1 deletion	1

Other mutations, copy number variations, or fusions that were detected but not classified by the Oncofocus Test as actionable by a known therapeutic targeted agent are not listed in the results section of this report.

Report Authorised by	Report reviewed by
Signed	Signed
printed Katherine Benton	printed Keeda Hardisty
Pre-Reg Clinical Scientist [X]	BMS [ ]
Pathologist [ ]	Clinical Scientist [X]
BMS [Senior] [ ]	

Suite 2, The Newnham Building, Chesterford Research Park,
Little Chesterford, Cambridge, CB10 1XL

+44 (0) 1223 785 327 - info@oncologica.com

Ireland

Bymac Centre, Northwest
Business Park, Blanchardstow, Dublin 15

+353 1 8604204

Italy

Parco Tecnologico della Sardegna
Pula, Località Piscinamanna

+39 02 808 88210